Unum Therapeutics Lands $12,000,000 Series A Funding

  • Feed Type
  • Date
    10/22/2014
  • Company Name
    Unum Therapeutics
  • Mailing Address
    One Broadway 4th Floor Cambridge, MA 02142 USA
  • Company Description
    Unum Therapeutics uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer.
  • Website
    http://www.unumrx.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $12,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    Unum plans to use capital raised through this financing to advance its lead candidate through initial proof-of-concept clinical studies, further enhance the ACTR technology, and establish partnerships to access tumor-specific antibodies for a pipeline of novel combination therapies.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy